Neukio Biotherapeutics
Main focus: Next-generation cell therapies for the treatment of cancer
Company stage: Pre-clinical
Diseases (gene editing): Haematological and solid cancers
Genome editing tool: Undisclosed
Funding stage: Private
Location: Shanghai, China
Website: https://www.neukio.com/en
Gene-editing partnerships: EdiGene
Neukio Biotherapeutics is a Shanghai-based start-up company, which aims to develop next-generation natural killer (NK) cell-based therapies. The company's developmental programmes are currently undisclosed, but it has recently formed a collaboration with EdiGene to utilise its gene-editing capabilities.